An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration.

MLA

Yang, Jie, et al. “An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-Small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration.” ACS Nano, vol. 16, no. 8, Aug. 2022, pp. 12590–605. EBSCOhost, https://doi.org/10.1021/acsnano.2c04159.

APA

Yang, J., Li, Y., Sun, J., Zou, H., Sun, Y., Luo, J., Xie, Q., A, R., Wang, H., Li, X., Wang, K., Yang, L., Ma, T., Wu, L., & Sun, X. (2022). An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration. ACS Nano, 16(8), 12590–12605. https://doi.org/10.1021/acsnano.2c04159

Chicago

Yang, Jie, Yingbo Li, Jiemei Sun, Hongyan Zou, Yige Sun, Jing Luo, Qian Xie, et al. 2022. “An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-Small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration.” ACS Nano 16 (8): 12590–605. doi:10.1021/acsnano.2c04159.